AstraZeneca PLC received approval from China's Food and Drug Administration to market its new lung cancer drug Tagrisso in the country, Bloomberg News reported, citing the company's announcement on its WeChat account.

The approval comes as the Chinese regulator vowed to hasten drug approvals, and is considering simplifying requirements for international clinical trials.

Representatives from the drugmaker couldn't immediately be reached for comment, according to the report.